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Abstract 
Context: Bone has recently been described as exhibiting properties of an endocrine 
organ by producing osteocalcin that increases insulin sensitivity and secretion in 
animal models. 
Objective and Design: We aimed to evaluate circulating osteocalcin in association with 
insulin sensitivity and insulin secretion in three different studies in nondiabetic 
subjects: one cross-sectional study in 149 men (using minimal model), and two 
longitudinal studies in two independent groups (one formed by 26 women, and the 
other by 9 men and 11 women), after a mean of 7.3 and 16.8% weight loss, and after a 
mean of 8.7% weight loss plus regular exercise. 
Results: In the cross-sectional study, circulating osteocalcin was associated with insulin 
sensitivity, mainly in lean subjects, and with insulin secretion (only in lean subjects). A 
mean of 16.8%, but not 7.3% weight loss, led to significant increases in circulating 
osteocalcin. However, a mean of 8.7% weight loss plus regular exercise led to the more 
pronounced effects on the serum osteocalcina concentration, which increased in 
parallel to reduced visceral fat mass, unchanged thigh muscle mass, and increased leg 
strength and force. The post intervention serum levels of osteocalcin were associated 
with both insulin sensitivity (r=0.49;P=0.03) and fasting triglycerides (r=0.54; 
P=0.01).The change in visceral fat was the parameter that best predicted the change in 
serum osteocalcin, once age, body mass index, and insulin sensitivity changes were 
controlled for (P=0.002). 
Conclusion: Circulating osteocalcin could mediate the role of bone as an endocrine 
organ in humans. (J Clin Endocrinol Metab 94: 237–245, 2009) 
Introduction 
Abnormalities of bone metabolism are well known to occur in subjects with obesity 
and type 2 diabetes. Even increased adiposity in children is a risk factor for fracture 
(Goulding, Jones, Taylor, Williams, & Manning, 2001). Patients with type 2 diabetes are 
prone to fracture, although their bone density may not be particularly low (Schwartz et 
al., 2001). The rate of bone turnover is decreased in patients with type 2 diabetes, as 
reflected by diminished expression of biomarkers of bone resorption and formation, 
including osteocalcin, an osteoblast-specific protein (Gerdhem, Isaksson, Akesson, & 
Obrant, 2005). In fact, several studies have previously demonstrated that serum 
osteocalcin was reduced in patients with type 2 diabetes (Bouillon et al., 1995; 
Pietschmann, Schernthaner, & Woloszczuk, 1988; Pedrazzoni et al., 1989; Rico, 
Hernandez, Cabranes, & Gomez-Castresana, 1989).  
Lee et al. (2007) have recently demonstrated in mice that bone regulates the 
insulin/glucose axis and energy metabolism. This is a fascinating new concept 
according to which the bone behaves as an endocrine organ by secreting osteocalcin, 
which leads to increased insulin secretion, lower blood glucose, increased insulin 
sensitivity, decreased visceral fat, and increased energy expenditure. In fact, mice 
lacking osteocalcina displayed decreased β-cell proliferation and insulin resistance, an 
abnormal amount of visceral fat, and increased serum triglyceride levels (Lee et al., 
2007). Similar information in humans is lacking.  
This recent description of osteocalcin as a bone-derived hormone impacting on insulin 
sensitivity in animal models provided us a framework to test whether circulating 
osteocalcin could also be associated with metabolic effects in humans. In fact, there 
are few studies that have evaluated circulating osteocalcin in relation to insulin 
sensitivity in humans. 
Subjects and Methods 
Cross- sectional study 
A total of 149 consecutive men [mean age, 50.2 ± 11.7 yr; range, 30–68 yr; mean body 
mass index (BMI) 27.6 ± 3.5 kg/m2 were recruited in an ongoing study dealing with 
insulin sensitivity in northern Spain. Subjects were randomly located from a census, 
and they were invited to participate. Participation rate was 71%. Inclusion criteria 
were: 1) BMI <40 kg/m2; 2) absence of systemic disease; and 3) absence of infection 
within the previous month. None of the control subjects were taking medications or 
had evidence of metabolic diseases other than obesity. Liver disease and thyroid 
dysfunction were specifically excluded by biochemical work-up. All subjects had fasting 
plasma glucose below 7.0 mM and were taking no medications. Type 2 diabetes was 
ruled out by an oral glucose tolerance test according to criteria from the American 
Diabetes Association. Insulin sensitivity was measured using the frequently sampled iv 
glucose tolerance test with minimal model analysis. Insulin secretion was calculated as 
the insulin area during the first 10 min of the frequently sampled iv glucose tolerance 
test. This test also provides the insulin disposition index, a parameter emerging from 
the model, which represents the ability of the pancreatic islets to compensate for 
insulin resistance.  
In brief, the experimental protocol started between 0800 and 0830 h after an 
overnight fast. A needle was inserted into an antecubital vein, and patency was 
maintained with a slow saline drip. Basal blood samples were drawn at -30, -10, and -5 
min, after which glucose (300 mg/kg body weight) was injected over 1 min starting at 
time 0, and insulin (Actrapid, 0.03 U/kg; Novo Nordisk, Bagsvaerd, Denmark) was 
administered at time 20 min. Additional samples were obtained from a contralateral 
antecubital vein up to 180 min. 
Effects of slight weight loss with or without regular physical activity 
Sedentary, nonsmoking, obese (BMI, 30-40 kg/m2) women, aged 40-60 yr, were 
recruited through an advertisement in a local newspaper. Before inclusion in the study, 
all candidates were thoroughly screened by an extensive medical history, resting and 
maximal exercise electrocardiograms, and blood pressure measurements. 
Cardiovascular, neuromuscular, arthritic, pulmonary, or other debilitating diseases as 
determined via one or all of the screening tools were reasons for exclusion from the 
study. None of the subjects received any medication. All subjects were carefully 
informed about the possible risks and benefits of the project and then provided 
written consent forms before participating in the study. This project was approved by 
the ethical committee of the regional health department.  
Participants were randomized to three groups: a control group (C; n = 7); a diet group 
(D; n = 8) with a caloric restriction of 500 kcal/d; and a diet and resistance training 
group (D+RT; n = 11) with the same caloric restriction as group D and a 16-wk 
supervised RT program of two sessions per week. During the 16 wk of the study, the 
subjects maintained their customary recreational physical activities (e.g. walking). The 
baseline characteristics of the subjects are presented in Table 1. 
Table1.  Baseline and follow-up characteristics of the slight weight loss study
Control (n= 7) 
age 51.5 ± 7.2 yr 
Diet (n= 8) 
age 51.6 ± 6.6  yr 
Diet + exercise (n= 11) 
age 47.7 ± 6.5 yr 






) 34.58 ± 3.90 34.38 ± 3.55 0.52 34.11 ± 3.89 31.62 ± 3.92 0.009 34.27 ± 2.78 31.33 ± 2.00 <0.0001 0.96 
Weight 88.68 ± 12.74 88.15 ± 11.74 0.506 87.22 ± 18.01 80.81 ± 16.64 0.012 88.08 ± 12.63 80.36 ± 9.11 <0.0001 0.98 
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1,232.09 








0.53 16,973.7 ± 4,787.1 
13,333.2 ± 
4,840.8 




1RM arms 34.28 ± 6.56 34.81 ± 6.38 0.20 30.31 ± 5.25 29.21 ± 5.86 0.175 32.95 ± 6.96 43.63 ± 7.61 <0.0001 0.47 
1RM legs  187.28 ± 30.47 188.71 ± 31.25 0.17 182.87 ± 39.80 205.37 ± 67.07 0.09 175.00 ± 33.68 274.54 ± 64.00 <0.0001 0.75 
HOMA  4.00 ± 1.54 3.01 ± 1.50 0.08 3.93 ± 2.61 2.92 ± 2.20 0.066 3.19 ± 1.53  2.13 ± 1.07 0.029 0.605 
Adiponectin  13.17 ± 3.24 12.67 ± 2.19 0.44  12.33 ± 4.85 12.68 ± 4.24 0.63 14.15 ± 4.55 12.90 ± 3.55 0.106 0.66 
Log sTNFR2  0.76 ±.03 0.75 ± 0.05 0.97  0.74 ± 0.10 0.69 ± 0.05 0.15 0.73 ± 0.15 0.75 ± 0.11 0.65 0.98 
Log osteocalcin 0.24 ± 0.35 0.07 ± 0.56 0.12  0.32 ± 0.31 0.31 ± 0.43 0.87 0.02 ± 0.39 0.34 ± 0.19 0.006 0.63 
Values are mean ± SD. AT, Adipose tissue; 1RM, one repetition maximum; sTNFR2, serum TNF receptor 2; WHR, waist-to-hip ratio. a ANOVA P for baseline
characteristics  among groups. 
Diet 
Diet was designed, in both D and D+RT groups, to reduce 500 kcal/d according to a 
previous evaluation of the habitual physical activity of each subject by accelerometry 
(TriTrac-R3D System, Software Version 2.04; Reining International, Madison, WI). This 
diet was designed to elicit a 0.5-kg weight loss per week. The C group was asked to 
maintain body weight. Throughout the 16-wk intervention period, body weight was 
recorded every 2 wk in both D and D+RT groups. Each subject of the intervention 
groups participated in a series of 1-h seminars (every 2 wk) wherein the dietitian 
taught proper food selection and preparation, eating behavior, control of portion sizes, 
and modification of binge eating and other adverse habits. The average compliance 
with the diet classes and the exercise sessions was above 95%. 
RT program 
The strength training program was a combination of heavy resistance and “explosive” 
strength training. The subjects were asked to report to the training facility two times 
per week for 16 wk to perform dynamic resistance exercise for 45–60 min per session. 
A minimum of 2 d elapsed between two consecutive training sessions. Each training 
session included two exercises for the leg extensor muscles (bilateral leg press and 
bilateral knee extension exercises), one exercise for the arm extensor muscle (the 
bench press), and four to five exercises for the main muscle groups of the body. Only 
resistance machines (Technogym, Gambettola, Italy) were used throughout the 
training period. In all the individual exercise sessions performed, one of the 
researchers was present to direct and assist each subject toward performing the 
appropriate work rates and loads. Lower and upper body maximal strength was 
assessed at wk 0 and 16 by using one repetition-maximum actions. 
Magnetic resonance (MR) 
The volumes of visceral and abdominal sc adipose tissue were measured by MR.MR 
imaging was performed with a 1Tmagnet (Magnetom Impact Expert; Siemens 
Corporation, New York, NY) using body coil. The subjects were examined in a supine 
position with both arms positioned parallel along the lateral sides of the body. The 
following procedures, in chronological order, were carried out: upper part of the body, 
subject repositioning; and lower part acquisition. We obtained a spoiled T1 weighted 
gradient-echo sequence with repetition time (TR) = 127 msec and echo time (TE) = 6 
msec. Each half body volume was scanned using two stacks, each containing 10 
contiguous 10-mm-thick slices. Each stack was acquired in 20 sec, and interleaved slice 
order was used. Afield of view of 500 mm was used, and all the stacks were acquired 
with breath holding. Depending on the height of the person, this resulted in a total of 
31–40 axial images per person. The total investigation time was about 5 min. 
MR imaging of both thighs was then obtained. T1-weighted sequence was used with a 
repetition time (TR) of 645 msec and a spin echo time (TE) of 20 msec. The field of view 
was 500 x 500 mm, and the matrix was 512 x 192. The slices were 10 mm thick, with 
no gap between the slices. The thighs were scanned using two stacks, each containing 
15 contiguous 10-mm-thick slices; the scan was performed axially from articular 
boundary of lowest external femoral condyle. The images were retrieved from the 
scanner according to a DICOM (Digital Imaging and Communications in Medicine) 
protocol. The acquired axial MR images were transferred to an external personal 
computer running Windows XP. The level of each abdominal image was labeled using 
sagittal scout images, referred to discal level. We used a specially designed image 
analysis software (SliceOmatic 4.3, Tomovision Inc., Montreal, Canada) for quantitative 
analysis of the images. 
Effects of moderate weight loss 
To evaluate further the effect of moderate weight loss on circulating osteocalcin after 
weight loss, 20 Caucasian obese volunteers (9 males, 11 females; age range, 21 to 66 
yr) attending the Endocrinology Department at the University Clinic of Navarra were 
recruited. Patients underwent a clinical assessment including medical history, physical 
examination, body composition analysis, and comorbidity evaluation, as well as 
nutritional interviews performed by a multidisciplinary consultation team. All subjects 
were nonsmokers. Patients with signs of infection were excluded. Obese patients were 
not receiving statins or any antidiabetic medication.  
Type 2 diabetes mellitus was defined following the criteria of the Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus based on both fasting plasma 
glucose concentrations and plasma glucose 2 h after an oral glucose tolerance test. 
Diet 
Weight loss was achieved by prescription of a diet providing a daily energy deficit of 
500-1000 kcal/d as calculated from the determination of the resting energy
expenditure through indirect calorimetry (Vmax29; SensorMedics Corporation, Yorba 
Linda, CA) and multiplication by 1.4 as indicated for sedentary individuals to obtain the 
patient’s total energy expenditure (Gomez-Ambrosi et al., 2007). This hypocaloric 
regime allows a safe and steady weight loss of 0.5-1.0 kg/wk when strictly followed 
and supplied 30, 54, and 16% of energy requirements in the form of fat, 
carbohydrates, and protein, respectively.  
In this study, body weight was measured with a digital scale to the nearest 0.1 kg, 
height was measured to the nearest 0.1 cm with a Holtain stadiometer (Holtain Ltd., 
Crymych, UK), and body fat was estimated by air-displacement-plethysmography (Bod-
Pod; Life Measurements, Concord, CA). Data for estimation of body fat by this 
plethysmographic method has been reported to agree closely with the traditional gold 
standard hydrodensitometry (underwater weighing) (Ginde et al., 2005).  
The experimental design was approved, from an ethical and scientific standpoint, by 
the Hospital’s Ethical Committees from all participant institutions in the three different 
studies, and volunteers gave their informed consent to participate in all the studies. 
Analytical determinations 
In all studies, blood samples were collected after an overnight fast in the morning to 
avoid potential confounding influences due to hormonal rhythmicity. Total serum 
triglycerides were measured through the reaction of glycerol-phosphate-oxidase and 
peroxidase. Intraassay and interassay coefficients of variation (CVs) were less than 4% 
for all these tests. 
Measurements of serum adiponectin and plasma osteocalcin were centralized in a 
single laboratory. Osteocalcin was measured by an Enzyme Amplified Sensitivity 
Immunoassay (EASIA) kit (DRG Instruments GmbH, Marburg, Germany). Sensitivity of 
the method, the detection limit, defined as the apparent concentration two SD values 
above the average OD at zero binding, was 0.4 ng/ml, and the intra- and interassay CVs 
were less than 10%. Serum adiponectin levels were measured by a commercially 
available ELISA kit (Linco Research, St. Charles, MO). The intra- and interassay CVs 
were less than 8%. The lowest level of adiponectin that can be detected by this assay is 
0.78 ng/ml. There was no cross-reactivity with other cytokines or hormones. 
In the cross-sectional study, serum glucose concentrations were measured in duplicate 
by the glucose oxidase method using a Beckman glucose analyzer II (Beckman 
Instruments, Brea, CA). Serum insulin levels were measured in duplicate by 
monoclonal immunoradiometric assay [IRMA or enzyme-amplified sensitivity 
immunoassay (EASIA), Medgenix Diagnostics, Fleunes, Belgium]. Intraassay and 
interassay CVs were similar to those previously reported (Gubern et al., 2006; 
Fernandez-Real et al., 2006). 
In the study of the effects of slight weight loss with or without regular physical activity, 
resting blood samples were drawn at wk 0 and 16. The subjects reported to the 
laboratory and sat quietly for 10–15 min before giving a blood sample. Basal glycemia 
was analyzed using an enzymatic hexokinase method (Roche Diagnostics, Mannheim, 
Germany). Serum insulin levels were measured in duplicate by monoclonal 
immunoradiometric assay (INSI-CTK Irma; DiaSorin, Madrid, Spain). Intraassay and 
interassay CVs were less than 5%. To estimate insulin resistance, the homeostatic 
model assessment (HOMA) index was calculated as fasting insulin concentration 
(μU/ml) x fasting glucose concentration (mmol/liter)/22.5. 
In the study of the effects of moderate weight loss, plasma glucose was analyzed by an 
automated analyzer (Roche/Hitachi Modular P800, Basel, Switzerland) as previously 
described (Gomez-Ambrosi et al., 2006). Insulin was measured by means of an 
enzyme-amplified chemiluminescence assay (Immulite, Diagnostic Products Corp., Los 
Angeles, CA). An indirect measure of insulin sensitivity was calculated from the fasting 
plasma glucose and insulin concentrations by using the quantitative insulin sensitivity 
check index (Katz et al., 2000; Gomez-Ambrosi et al., 2002). 
Statistical analysis 
Pearson’s correlation was used to evaluate the associations among continuous 
variables. Those parameters that did not follow a normal distribution were log-
transformed. Comparisons of quantitative variables among groups were made using 
ANOVA. Multiple regression models were used to assess the influence of osteocalcin 
on insulin sensitivity, taking into account potential factors associated with this variable 
such as BMI and waist-to-hip ratio. The models were built in a customized way by 
means of the enter method, which takes into account the simultaneous influence of all 
variables; this is a procedure for variable selection in which all variables in a block are 
entered in a single step. We chose this conservative method given the relatively low 
number of subjects studied. Furthermore, regression diagnostics were checked by 
using the inverse normal plot of the residuals and plots of the residuals against the 
fitted values. Influence analyses were also performed by means of Cook’s D. Moreover, 
the problems of colinearity were solved by centering some of the variables. The 
statistical package used was Stata v.8 (StataCorp, College Station, Texas). Levels of 
statistical significance were set at P < 0.05. 
Results 
Cross-sectional study 
We evaluated 149 men, aged 50.2 ± 11.7 yr, with mean BMI 27.6 ± 3.5 kg/m2, a 
median insulin sensitivity of 2.35*10-4*min-1*mU/liter (interquartile range, 1.23–3.2), 
and a median insulin secretion of 359.1 mU/liter*min-1 (interquartile range, 186.6–
511.1). Median circulating osteocalcina was 6.1 (interquartile range, 3.5-8.1) ng/ml. 
Osteocalcin was positively linked to insulin sensitivity among these 149 otherwise 
healthy men (r = 0.23; P = 0.006; Fig. 1). The statistical power of this association was 
81% (α = 0.05, β = 0.20).
Interestingly, the association appeared stronger in lean subjects (BMI <25 kg/m2) (Fig. 
1, enclosed legend), although the comparison between slopes did not reach statistical 
significance (P = 0.3). Among lean subjects, osteocalcin was the most significant factor 
impacting on insulin sensitivity (45% of its variance), even after accounting for the 
effects of age, BMI, and waist diameter in a multiple linear regression analysis. Among 
lean subjects, we also observed a positive association between circulating osteocalcin 
and insulin secretion (r = 0.41; P = 0.03) and the insulin disposition index (r = 0.43; P = 
0.02). Circulating adiponectin was available in 137 of these subjects and showed a 
positive association with osteocalcin (r = 0.19; P = 0.02). 
Figure 1. Linear relationship between circulating osteocalcin and insulin sensitivity in 149 men 
of the cross-sectional study (single line and correlation coefficient) and in lean men (95% 
confidence interval for the mean and correlation coefficient in the upper left corner). Lean 
subjects are defined as having a BMI less than 25 kg/m2; overweight as BMI at least 25 but less 
than 30 kg/m2; and obese as BMI greater than 30 kg/m2. We used the nontransformed value of 
osteocalcin because the Kurtosis and skewness values were closer to 0 than the log-
transformed value in this population. 
Effects of weight loss on circulating osteocalcin 
Given this cross-sectional association, we also aimed to evaluate the effects of weight 
loss and physical exercise on circulating osteocalcin. Twenty-six obese women were 
randomized to follow a structured RT program and a hypocaloric diet (D+RT; n=11), 
compared with only a hypocaloric diet (D; n = 8) and a control group (C; n = 7), in which 
no action was taken. Baseline characteristics were similar in the three groups (Table 1). 
Serum osteocalcin was negatively associated with insulin resistance (HOMA value, 
r = - 0.43; P = 0.03) and positively with circulating adiponectin (r = 0.45; P = 0.02). 
Baseline osteocalcin was not significantly associated with total fat (r = - 0.27; P = 0.18), 
visceral fat (r = - 0.24; P = 0.2), or fasting triglycerides (r = 0.01; P = 0.9).  
After 16 wk, no significant changes were observed in the different parameters 
evaluated in the control group (Table 1). In the diet group, a 7.3% weight loss was 
accompanied by reduced total and visceral fat mass and thigh muscle mass. Insulin 
sensitivity tended to improve. No significant changes in serum osteocalcina 
concentrations were observed. In the diet plus RT group, despite the fact that weight 
loss was of similar magnitude (- 8.7%), osteocalcin increased significantly (Fig. 2). The 
statistical power of this change in serum osteocalcin was 96% (α = 0.05, β = 0.20). This
was observed in parallel with reduced visceral fat mass, unchanged thigh muscle mass, 
and increased leg strength and force (Fig. 3). In all subjects as a whole (n = 26), the 
change in circulating osteocalcin was significantly associated with the change in 
visceral fat (r = - 0.59; P = 0.001). However, in the subgroup analysis, this relationship 
was not significant in the control group (r = 0.25; P = 0.6) or in the diet group 
(r = - 0.40; P = 0.3). 
Figure 2. Changes in circulating osteocalcin in obese women (n = 26) enrolled in the slight 
weight loss intervention.  A, Control subjects, in whom no action was taken (n = 7); B, diet-
induced weight loss (n = 8); C, weight loss induced by diet plus regular exercise (n = 11). Edges 
of gray box indicate 25th and 75th percentiles. Horizontal line in middle of box depicts median. 
Whiskers indicate minimum/maximum values.
In the intervention groups (both D and D+RT, n = 19) the post intervention serum 
levels of osteocalcin were associated with both insulin resistance (r = - 0.49; P = 0.03) 
and fasting triglycerides (Fig. 3D). However, we did not observe significant 
relationships between the change in circulating osteocalcina and the change in fasting 
triglycerides. In all subjects as a whole (n = 26), the change in visceral fat was the single 
parameter that best predicted the change in serum osteocalcin, once age, BMI, and 
insulin sensitivity changes were controlled for (P = 0.002) (Table 2). When the change 
in leg muscle strength was introduced in the model, both variables contributed to 30% 
of the variance in changing serum osteocalcin (Table 2). 
We then questioned whether the magnitude of weight loss was insufficient to impact 
on circulating osteocalcin concentration. To this end, we studied subjects that 
underwent a more prolonged period of treatment, achieving a mean weight loss of 
-16.8%. The characteristics of these subjects are shown in Table 3. Baseline osteocalcin
was not significantly associated with insulin sensitivity (r = 0.25, P = 0.3) and tended to 
be negatively associated with total fat mass   (r = - 0.33, P = 0.1). In these subjects, 
mean osteocalcin was increased after weight loss (Fig. 4). 
Table 2. Multiple linear regression analysis with the change in circulating 
osteocalcin as dependent variable in the slight weight loss study 
Change in osteocalcin β P value β 
P value 
Age -0.17 0.34 -0.009 0.85 
Change in BMI -0.12 0.57 -0.19 0.87 
Change in insulin sensitivity -0.10 0.58 -0.12 0.94 
Change in visceral fat -0.52 0.002 -0.46 0.005 
Change leg muscle strenght 0.51 0.002 
Ajusted R
2
 0.24 0.30 
The statistical power of this change in serum osteocalcin was 78% (α = 0.05, β = 0.20).
However, we found no associations between the change in serum osteocalcin and 
changing insulin resistance, circulating adiponectin, or triglycerides (r values between 
- 0.32 and 0.26, P > 0.1). Interestingly, among men, the decrease in waist diameter
tended to be associated with the increase in osteocalcin but this was not statistically 
significant (r = - 0.51, P = 0.1, n = 9).  





n 20 20 P 
Age (yr) 43.4 ± 9.4 44.1 ± 9.2 
Body weight (kg) 109 ± 7 91 ± 4  < 0.001 
BMI (kg/m2)  38.0 ± 2.0  32.0 ± 2.1 < 0.0001 
Body fat (%)  45.9 ± 2.0  38.6 ± 2.1 < 0.0001 
Waist circumference (cm) 115 ± 4 103 ± 3 
WHR 0.95 ± 0.02 0.94 ± 0.02 0.175 
Glucose (mmol/liter) 5.6 ± 0.2   5,1 ± 0,1 0.043 
Insulin (mU/ml) 21.4  ± 5.2 11.8 ± 1.7 0.112 
QUICKI  0.312 ± 0.009 0.341 ± 0.012 0.031 
Leptin (ng/ml) 39.2 ± 12.1 25.4 ± 10.2 0.044 
To convert glucose to milligrams per deciliter, divide by 0.05551.  WHR, Waist-to hip ratio. 
Figure 3. Factors associated with changing osteocalcin in obese women (n =26) enrolled in the slight weight loss intervention. Variables associated with the 
change in serum osteocalcin: A, change in visceral adipose tissue; B, absolute leg force (1-rm); and C, changes in leg force. D, Log osteocalcin was associated 
with fasting triglycerides only after weight loss in the intervention group as a whole: diet only and diet + RT groups together. E, Relationship between the 
change in saturated fatty acid intake and change in osteocalcin after weight loss. The coefficients shown only represent open circles in all panels. 
Figure 4. Obese men and women (n = 20) enrolled in the moderate weight loss intervention. Changes in BMI (left panel) and osteocalcin (right panels). 
Edges of gray box indicate 25th and 75th percentiles. Horizontal line in middle of box depicts median. Whiskers indicate minimum/maximum values. 
Discussion 
Summarizing the associations with insulin sensitivity, we found that fasting osteocalcin 
was associated with insulin sensitivity cross-sectionally in 149 men and in 26 obese 
women with a wide range of BMI, but not in 20 obese men and women with a low BMI 
range. The change in circulating osteocalcin was significantly associated with the change 
in insulin sensitivity in the slight weight loss group (both D and D+RT groups,     r = - 0.50; 
P = 0.02; n = 19) but not in the moderate weight loss group. 
The main findings of this study are: 1) the association between circulating osteocalcin and 
insulin sensitivity; 2) the association between osteocalcin and insulin secretion and insulin 
disposition index among lean men; 3) the observation that slight diet-induced weight loss 
per se did not lead to significant changes in serum osteocalcin concentration; 4) a weight 
loss of similar magnitude plus regular physical activity resulted in increased circulating 
osteocalcin; 5) the increase in serum osteocalcin concentration was associated with 
changes in visceral fat mass and, importantly, with changes in leg muscle strength; and 6) 
moderate weight loss also resulted in increased osteocalcin but without relationship to 
insulin sensitivity or fasting triglycerides. 
In parallel with the findings described in experimental animals (Lee et al., 2007), we 
found that the baseline circulating osteocalcin concentration was associated with insulin 
sensitivity and secretion and circulating adiponectin (lean and obese men and women). 
After slight weight loss, osteocalcin correlated with fasting triglycerides in obese women. 
Osteocalcin knockout mice showed increased visceral fat (Lee et al., 2007). In our study, 
serum osteocalcin significantly increased in parallel to reduced visceral fat mass after diet 
and regular exercise in obese women .In the slight weight loss study, baseline 
osteocalcina was not significantly different among groups (Table 1). By chance, mean 
values of osteocalcin were higher in the D+RT group compared with the other groups. 
This difference was not statistically significant, even if we compared this group to the 
remaining subjects (P = 0.3). In fact, baseline mean log osteocalcina in the D+RT group 
was very similar to that present in the control group after follow-up. 
It could be argued that the change in insulin resistance and fat mass was, to some extent, 
similar in the D group and the D+RT group (the change in insulin resistance in the D group 
did not reach statistical significance). However, the most striking differences between 
these groups were the change in leg force, which was strongly related with the change in 
serum osteocalcin in univariant and multivariate analysis. Thigh muscle mass was 
unchanged after diet plus regular exercise in association with increased leg strength and 
force. In contrast, in the D group, thigh muscle mass was significantly decreased after 
16wk (Table 1). In a previous study, as little as a 5%weight loss plus regular exercise also 
led to increased osteocalcin (Hinton, Rector, & Thomas, 2006). 
There is a considerable body of evidence gathered from studies over the past half century 
indicating that regular physical activity reduces the risk of cardiovascular disease. Regular 
physical activity is particularly beneficial to individuals with insulin-resistant conditions, 
such as obesity, type 2 diabetes, and the metabolic syndrome (Gill & Malkova, 2006). 
Although the postexercise increase in muscle insulin sensitivity has been characterized in 
considerable detail, the basic mechanisms underlying this phenomenon remain a mystery 
(Holloszy, 2005). Like exercise, stimulation of muscles to contract in situ results in an 
increase in insulin sensitivity (Cartee & Holloszy, 1990). In contrast, stimulation of 
muscles immersed in Krebs-Henseleit-bicarbonate buffer to contract in vitro does not 
result in enhanced insulin sensitivity (Holloszy, 2005; Cartee & Holloszy, 1990; Gao, Gulve, 
& Holloszy, 1994). The explanation for this finding was that an as-yet-unidentified serum 
protein must be present during contractile activity in order for the increase in insulin 
sensitivity to occur (Gao et al., 1994). The mechanism responsible for the permissive 
effect of serum has not yet been elucidated. Also, like contractile activity, the effects of 
exercise, hypoxia, and 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR, a 
pharmacological activator of AMPK) on insulin sensitivity require the presence of serum 
during the treatment period (Fisher, Gao, Han, Holloszy, & Nolte, 2002). 
We propose that osteocalcin represents this missing link in the exercise-induced 
improvement in insulin sensitivity. Exercise is thought to act on the skeleton through 
muscle pull, producing strains on the skeleton that are perceived by bone cells. We 
observed that a change in leg force was associated with a change in serum osteocalcin 
concentration (Fig. 3C). Exercise may stimulate increased secretion of osteocalcin by 
bone that positively impacts on insulin secretion and insulin sensitivity. We further 
propose that diet-induced weight loss and exercise lead to changes in insulin sensitivity 
by different mechanisms. Although prolonged dieting induced changes in circulating 
osteocalcin, the magnitudes of these changes were not associated with the metabolic 
profile. 
Moderate, but not slight, weight loss led to significantly increased circulating osteocalcin 
levels, possibly indicating only increased bone turnover. This supports previous findings in 
which osteocalcin increased after diet-induced weight loss (Viapiana et al., 2007; Bowen, 
Noakes, & Clifton, 2004). As previously suggested, the overall increase in bone turnover 
may be unfavorable for maintaining bone mass after diet induced weight loss (Viapiana et 
al., 2007). A study of the ratio of undercarboxylated osteocalcin to total osteocalcin after 
diet and after exercise might provide the clue for the study of their association with 
insulin sensitivity. 
Not all reports on the effects of weight loss or exercise on circulating osteocalcin levels 
are concordant. Villareal et al. (2006) reported no significant changes in osteocalcin levels 
with weight loss due to caloric restriction. However, no obese subjects were included in 
this study (Villareal et al., 2006). Interestingly, these authors found that exercise was 
associated with preservation of bone mineral density that could be mediated through 
exercise-induced bone loading (Villareal et al., 2006). We here suggest that bone loading 
could elicit increased osteocalcin production. On the other hand, weight gain also led to 
increased osteocalcin in patients with anorexia nervosa, possibly indicating, again, 
increased bone remodeling (Ricci et al., 1998).  
Several studies have previously demonstrated that serum osteocalcina was reduced in 
patients with type 2 diabetes (Bouillon et al., 1995; Pietschmann et al., 1988; Pedrazzoni 
et al., 1989; Rico et al., 1989). To our knowledge, this would be the first study evaluating 
osteocalcina in association with insulin sensitivity in humans, and the first study showing 
exercise-induced changes in circulating osteocalcina in association with insulin sensitivity, 
visceral fat mass, and muscle strength. However, the lack of data on undercarboxylated 
osteocalcin is a limitation of this study. Lee et al. (2007) reported that undercarboxylated 
osteocalcin was the active form of osteocalcin in rodent models.  
In summary, our findings suggest that osteocalcin might be an active regulator of insulin 
sensitivity by bone. 
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